Serenoa Repens in the hands of the modern urologist

Eleftherios Teperikidis, Benjamin Polatidis

Abstract


Background: Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate gland that affects around 50% of men between the ages of 50 and 60 years old. The application of Serenoa Repens in the treatment of the symptoms of stage I & II BPH is a therapeutic option that is present in the urologist’s agenta for nearly three decades. The purpose of this work is the complete evaluation of existing literature on Serenoa Repens (in-vitro experiments, clinical trials and institutional monographs), summing up clinical trial references in an appendix and raising the necessary issues as far as raw material quality is concerned, providing a good point of reference to the contemporary urologist

Methods: A complete review of the available literature on the effect of the lipidosterolic extract of Serenoa Repens in Benign Prostatic Hyperplasia was conducted. Studies were collected via Pubmed.org, and an analytical appendix was formed, providing the full spectrum of available data.

Results: There are contradictions in the available literature, especially in between the results of 1984 to 2014 clinical trials and the available monographs. Contemporary clinical trial publications don’t make any reference to the specifications prescribed by European Pharmacopoieia, which are the only quality markers available.

Conclusion: Future research should focus on and take into account the specifications available in European Pharmacopoieia concerning the content and method of production, providing thorough quantitative analysis of the contents of the extract used in trials.


Keywords


Serenoa Repens; Saw Palmetto; Benign Prostatic Hyperplasia

Full Text:

PDF

References


Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 2009; 32(8): 637-647.

American Botanic Council, The Commision E Monographs, Saw Palmetto Berry. Retrieved Online from http://cms.herbalgram.org/commissione/Monographs/Monograph0330.html.

Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon) : a 5 alpha-reductase types I and II inhibitor - new evidence in a coculture model of BPH; Prostate 1999; 40: 232-241.

Bluementhal M, Busse WR, Goldberg A, et al (eds) Klein S, Rister RS.(trans) The complete German Commission E Monographs - Therapeutic Guide to Herbal Medicines. Austin, TX: American Botanical Council; 1998.

Blumenthal M, Goldberg A, Brinckmann J. Herbal Medicine - Expanded Commission E Monographs. Newtonm, MA : Integrative Medicine Communications 2000; 335 - 340.

Blumenthal Mark, The ABC Clinical Guide to Herbs Online, American Botanic Council, 2013 :p.p 309 – 319, Αccessed online athttp://abc.herbalgram.org/site/DocServer/LookInsideTheGuide.pdf?docID=341.

Booker A, Suter A, Krnjic A, et al. A phytochemical comparison of saw palmetto products using gas chromatography and 1H nuclear magnetic resonance spectroscopy metabolomic profiling. J. Pharm. Pharmacol 2013; 66: 811- 822.

Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 2004 Apr; 93: 751-756.

Breu W, Hagenlocher M, Redl K et al. Anti-inflammatory activity of Sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism (in German). Arzneimittelforschung 1992; 42: 547 -551.

Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatric hyperplasia. Urology 2003; 61: 1-7.

Committee on Herbal Medicinal Products (HMPC), 2014. European Medicines Agency, Assessment report on Serenoa Repens small, fructus. 24 November 2014 EMA/HMPC/137250/2013.

Committee on Herbal Medicinal Products (HMPC), 2014. European Medicines Agency, European Union herbal monograph on Serenoa Repens (W. Bartram) Small, fructus. 24 November 2014 EMA/HMPC/280079/2013.

De Monte C, Carradori S, Granese A, et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa Repens extracts for the treatment of lower urinary tract symptoms. BMC Urol 2014;14 :63.

Elliott HL, McLean K, Sumner DJ, et al. Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers. Clin Pharmacol Ther 1981; 29: 303-309.

European Directorate for the Quality of Medicines & Healthcare, European Pharmacopoeia, 8th edn. Saw Palmetto extract, Sabalis serrulatae extractum; 1377-1379. Accessed online at https://www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html.

1Feifer AH, et al. Analytical Accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol 2002; 168: 150-154.

Gerber G., Saw Palmetto for the treatment of men with lower urinary tract symptoms. J.Urol 2000; 163: 1408 - 1412.

Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa Repens. Prostate Cancer Prostatic Dis 2004; 7 :195-200.

Iehle C, Dιlos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alphareductase isoforms. A comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995 ; 54: 273-279

Iglesias Gato D, Carsten T, Vesterlund M, et al. Androgen- independent effects of Serenoa Repens Extract (Prostasan) on Prostatic Epithelial Cell Proliferation and Inflammation. Phytother. Res. 2012; 26: 259-264.

Latil A, Libon C, Templier M, et al. Hexanic Lipidosterolic extract of Serenoa Repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int 2012; 110: 301-317.

Liang T, Liao S. Inhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids. Biochem J 1992; 285: 557- 562.

Mac Donald R, Tacklind J. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012; 109(12): 1756-1761.

Miller K. Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents. Drugs 1994; 48: 868-887.

Minutoli L, Altavilla D, Marini H, et al. Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene. J Biomed Sci 21:19.

Niederprum H J, Schweikert H U, Thuroff J W, Zanker K S. Inhibition of steroid 5α-reductase activity by aliphatic fatty acids. Candidates for chemoprevention of prostate cancer. Ann. N. Y. Acad. Sci 1995; 768 : 227-230.

Paubert - Braquet M, Mencia HJ, Cousse H, et al. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 299.

Penugonda K, Lindshield BL. Fatty Acid and Phytosterol Content of Commercial Saw Palmetto Supplements. Nutrients 2013; 5: 3617-3633.

Sanofi-Aventis US LLC, Product Information: UROXATRAL(R) oral extended-release tablets, alfuzosin HCl oral extended-release tablets, Bridgewater, NJ, Apr 1, 2008.

Silverio F, Steg A. New Trends in Bladder Cancer Chemotherapy – New Trends in BPH Etiopathogenesis. Proceedings of the International Workshop in Urology; Acta Medica 1988; 293.

Scaglione F, Lucini V, Pannacci M, et al. Comparison of the potency of 10 different brands of Serenoa Repens extracts, Eur.Rev.Med.Pharmacol.Sci 2012; 16: 569-574 .

Seideman P, Grahnen A, Haglund K, et al. Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 1982; 13: 865-870.

Silvestri I, Cattarino S, Agliano A. Effect of Serenoa Repens (Permixon) on the expression of inflammation related genes: analasysis in primary cell cultures of human prostate carcinoma. J Inflamm 2013;10 :11.

The World Health Organization, Fructus Serenoa Repentis, WHO Monographs on Selected Medicinal Plants vol 2. 1999; 285 – 299 Accessed online at http://apps.who.int/medicinedocs/en/d/Js4927e/

Weisser H, Tunn S, Behnke B, Krieg M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia. Prostate 1996; 28: 300-306.

Wilde M, Fitton A & McTavish D. Alfuzosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993; 45:410-429.

Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009; 15(2): CD001423.

Yang Y, Ikezoe T, Zheng Z, et al. Saw Palmetto induces growth arrest and apoptosis of androgen‐dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int J Oncol 2007; 31:593-600.




DOI: http://dx.doi.org/10.19264/hj.v29i1.109